Today, we announced our financial results for Q2 2025. This quarter, we continued to successfully execute against our focused strategy to advance our lead indications in #SPS and #MG. Read the full release: bit.ly/4lsVMOd

Our CEO, Warner Biddle, will share our latest company highlights during several upcoming investor conferences. Learn more: bit.ly/4mv4FrD #WellsFargoHealthcare #MorganStanleyHealthcare #HCWainwright

Join our virtual KOL IR event today at 11:00 am ET to hear updates on our neuroimmunology CAR T franchise, including our KYSA-6 Phase 3 trial design for #MG: bit.ly/3HNtksz More details about the event can be read here: bit.ly/3HxRsPX

Yesterday, we shared how Kyverna is leading the way in changing the standard of care for patients with autoimmune diseases like #SPS and #MG, and what the future looks like for our neuroimmunology CAR T franchise. Watch the recording from yesterday’s event here:

We are pleased to announce that interim data from the Phase 2 portion of the KYSA-6 clinical study in #MG will be presented at #AANEM in October. Read our press release for more details: bit.ly/3VOnOZU

We are looking forward to discussing the latest advancements and opportunties in #CARTCellTherapy at the annual CAR-TCR Summit this week. More details about our participation can be found in the summit agenda: bit.ly/4prElAA #CARTCR2025

Today, we announced that updated data from the Phase 1 investigator-initiated trials in #MS will be presented at #ECTRIMS2025. This encouraging data with our investigational CAR T-cell therapy, KYV-101, highlights the broader potential of our therapy within

Join us in spreading the word about our #MyastheniaGravis Phase 3 clinical trial, KYSA-6. If you or someone you know is affected by MG, learn more at myastheniagravistrials.com #CARTcelltherapy #neuroimmunology #MG

We’re looking forward to next week’s Cell & Gene Meeting on the Mesa to share the latest developments in advancing CAR T-cell therapy for autoimmune diseases. Find Kyverna in Phoenix: bit.ly/4gN8iaI #CGMesa25 #MeetingontheMesa #CARTcelltherapy

We were proud to support Myasthenia Gravis Foundation of America at the MG Walk in SoCal and Community Health Fair in Houston. Thank you for the opportunity to educate patients, caregivers, and advocates about Kyverna's CAR T-cell therapies. #MGCommunity #MGFA #AutoimmuneAwareness #PatientAdvocacy

Join us next week on Wednesday 10/29 for an IR conference call where we will be discussing interim data from the KYSA-6 Phase 2 clinical trial investigating KYV-101 in #MG. Details on how to register can be found here: bit.ly/3KUY2kR

We are excited to share that new data from the Phase 1 portion of an investigator-initiated Phase 1/2 trial in #RheumatoidArthritis will be presented at American College of Rheumatology Convergence 2025. Find more details in our latest release: bit.ly/47Ha6yM #ACR25

We will present positive interim data from the Phase 2 portion of our registrational KYSA-6 trial with our investigational CAR T-cell therapy, KYV-101, in generalized #MG today at AANEM. Read more: bit.ly/4hS0HIt

We have closed a loan facility for up to $150 million with Oxford Finance, which will strengthen our financial flexibility and support the advancement of our late-stage indications in #MG and #SPS. Read more here: bit.ly/3WVn71P

We look forward to having our CEO, Warner Biddle, participate in the upcoming Jefferies Global Healthcare Conference in London on Monday, November 17. Learn more: bit.ly/3LCfeeZ

Today, we announced our financial results for Q3 2025, which demonstrate continued execution of meaningful clinical and corporate milestones to advance our #neuroimmunology #CART franchise. Read the full release: bit.ly/441xRiL